[Federal Register Volume 62, Number 154 (Monday, August 11, 1997)]
[Notices]
[Page 42998]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-21085]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 94N-0193]


Robert E. Sacher; Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is issuing an order 
under the Federal Food, Drug, and Cosmetic Act (the act) permanently 
debarring Dr. Robert E. Sacher, 117 Deer Path Lane, Weston, MA 02193, 
from providing services in any capacity to a person that has an 
approved or pending drug product application. FDA bases this order on a 
finding that Dr. Sacher was convicted of a felony under Federal law for 
conduct relating to the regulation of a drug product under the act. Dr. 
Sacher has failed to request a hearing and, therefore, has waived his 
opportunity for a hearing concerning this action.

EFFECTIVE DATE: August 11, 1997.

ADDRESSES: Application for termination of debarment to the Dockets 
Management Branch (HFA-305), Food and Drug Administration, 12420 
Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:  Leanne Cusumano, Center for Drug 
Evaluation and Research (HFD-7), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-594-2041.

SUPPLEMENTARY INFORMATION: 

I. Background

    On June 1, 1992, the U.S. district court for the District of 
Massachusetts entered judgment against Dr. Robert E. Sacher for one 
count of corruptly influencing, obstructing, and impeding the due 
administration of justice in an administrative proceeding of FDA, a 
Federal felony under 18 U.S.C. 1505.
    As a result of this conviction, FDA served Dr. Sacher by certified 
mail on November 25, 1994, a notice proposing to permanently debar him 
from providing services in any capacity to a person that has an 
approved or pending drug product application, and offered him an 
opportunity for a hearing on the proposal. The proposal was based on a 
finding, under section 306(a)(2)(B) of the act (21 U.S.C. 
335a(a)(2)(B)), that Dr. Sacher was convicted of a felony under Federal 
law for conduct relating to the regulation of a drug product. Dr. 
Sacher did not request a hearing. His failure to request a hearing 
constitutes a waiver of his opportunity for a hearing and a waiver of 
any contentions concerning his debarment.

II. Findings and Order

    Therefore, the Director of the Center for Drug Evaluation and 
Research, under section 306(a) of the act, and under authority 
delegated to her (21 CFR 5.99(b)), finds that Dr. Robert E. Sacher has 
been convicted of a felony under Federal law for conduct relating to 
the regulation of a drug product.
    As a result of the foregoing finding, Dr. Robert E. Sacher is 
permanently debarred from providing services in any capacity to a 
person with an approved or pending drug product application under 
sections 505, 507, 512, or 802 of the act (21 U.S.C. 355, 357, 360b, or 
382), or under section 351 of the Public Health Service Act (42 U.S.C. 
262), effective August 11, 1997 (sections 306a(c)(1)(B) and 
(c)(2)(A)(ii) and 201(dd) of the act (21 U.S.C. 321(d))). Any person 
with an approved or pending drug product application who knowingly uses 
the services of Dr. Sacher, in any capacity, during his period of 
debarment, will be subject to civil money penalties (section 307(a)(6) 
of the act). If Dr. Sacher, during his period of debarment, provides 
services in any capacity to a person with an approved or pending drug 
product application, he will be subject to civil money penalties 
(section 307(a)(7) of the act). In addition, FDA will not accept or 
review any abbreviated new drug applications or abbreviated antibiotic 
drug applications from Dr. Sacher during his period of debarment.
    Any application by Dr. Sacher for termination of debarment under 
section 306(d)(4) of the act should be identified with Docket No. 94N-
0193 and sent to the Dockets Management Branch (address above). All 
such submissions are to be filed in four copies. The public 
availability of information in these submissions is governed by 21 CFR 
10.20(j). Publicly available submissions may be seen in the Dockets 
Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

    Dated: July 18, 1997.
Janet Woodcock,
Director, Center for Drug Evaluation and Research.
[FR Doc. 97-21085 Filed 8-8-97; 8:45 am]
BILLING CODE 4160-01-F